Weld Capital Management’s Travere Therapeutics TVTX Stock Holding History

Weld Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-13,025	Closed	-$190K	–	636
2020 Q1	$190K	Buy	+13,025	New	+$196K	0.1%	325
2019 Q2	–	Sell	-12,185	Closed	-$276K	–	928
2019 Q1	$276K	Sell	12,185 -14,172	-54%	-$313K	0.05%	526
2018 Q4	$596K	Buy	+26,357	New	+$656K	0.13%	290

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Weld Capital Management's TVTX Position: Q2 2020 in Review

Weld Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2020, closing a stake of 13,025 shares — an estimated $190K sold.

Weld Capital Management first reported a position in TVTX in Q4 2018 and held it in 3 quarters. The position peaked at $596K in Q4 2018. 147 funds tracked by Wall St. Rank hold TVTX as of Q2 2020.

Weld Capital Management reported no remaining Travere Therapeutics position as of Q2 2020 after selling out during the quarter.
Weld Capital Management sold 13,025 Travere Therapeutics shares in Q2 2020, an estimated $190K.
Weld Capital Management first reported a position in Travere Therapeutics in Q4 2018 and held it in 3 quarters.
Weld Capital Management's Travere Therapeutics position peaked at $596K in Q4 2018.
147 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2020.

Based on Weld Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.